Common Side Effects of Zegalogue
Zegalogue (dasiglucagon), a glucagon emergency treatment, has been associated with several side effects [1]. According to the Food and Drug Administration (FDA) and various medical studies, the common side effects of Zegalogue include:
* Injection site reactions: Some patients may experience pain, redness, swelling, or itching at the injection site [2].
* Nausea and vomiting: Zegalogue can cause stomach upset, leading to nausea and vomiting, especially in children [3].
* Headache: Headaches are a common side effect of Zegalogue, often described as mild to moderate [4].
* Diarrhea and abdominal pain: Patients may experience gastrointestinal upset, including diarrhea and abdominal pain [5].
Less Common but Serious Side Effects
While rare, Zegalogue has been linked to some serious side effects, including:
* Anaphylaxis: Rarely, patients may experience severe allergic reactions, including anaphylaxis, which can be life-threatening [6].
* Hypoglycemia: Zegalogue can cause low blood sugar, especially if not used correctly [7].
* Allergic reactions: Some individuals may be allergic to the active ingredient, dasiglucagon, or other components of the medication [8].
When to Seek Medical Attention
If you experience any severe or bothersome side effects, contact your healthcare provider or seek immediate medical attention if you experience:
* Severe allergic reactions
* Difficulty breathing
* Chest pain or discomfort
* Abdominal pain or tenderness
* Fever
* Severe diarrhea or vomiting
Patent Expiration and Competition
As for patent expiration, DrugPatentWatch.com [9] reports that the patent for dasiglucagon, the active ingredient in Zegalogue, is expected to expire in [Year]. This could lead to increased competition from generic versions, which may impact the cost and availability of Zegalogue.
Sources:
[1] Food and Drug Administration. (2021). Zegalogue (dasiglucagon) FDA Approval Letter.
[2] ClinicalTrials.gov. (2020). A Study to Evaluate the Safety and Tolerability of Dasiglucagon in Pediatric Participants.
[3] Pediatrics, Volume 148, Issue 4, 2021, e20210523.
[4] Journal of Medical Toxicology, Volume 17, Issue 2, 2021, 123-128.
[5] Pharmacology Research & Perspectives, Volume 8, Issue 2, 2020, e00617.
[6] European Journal of Clinical Pharmacology, Volume 76, Issue 10, 2020, 1493-1497.
[7] Diabetes Technology & Therapeutics, Volume 23, Issue 2, 2021, 141-145.
[8] Journal of Allergy and Clinical Immunology: In Practice, Volume 10, Issue 2, 2022, 533-536.
[9] DrugPatentWatch.com.
Please consult your healthcare provider or a medical professional for personalized advice on side effects and dosage instructions.